Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A four-part study to evaluate the safety, tolerability, and efficacy of enoxaparin for inhalation, alone and in combination with N-acetylcysteine in healthy volunteers and hospitalised COVID-19 patients

Next Previous
X
Search
Trial Profile

A four-part study to evaluate the safety, tolerability, and efficacy of enoxaparin for inhalation, alone and in combination with N-acetylcysteine in healthy volunteers and hospitalised COVID-19 patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AT-H201 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Atossa Therapeutics

    • Most Recent Events

    • 28 Jul 2022 According to an Atossa Therapeutics media release, part D of the study will not be conducted because of the rapidly shifting COVID-19 treatment landscape and the introduction of effective vaccines limiting hospitalizations.
    • 28 Jul 2022 According to an Atossa Therapeutics media release, the company has completed dosing participants in Part C of the trial in Australia.
    • 20 Apr 2022 According to an Atossa Therapeutics media release, Parts A, B and C of the study are being conducted by Avance Clinical Pty Ltd and the company commencing parts C and D of the study is subject to additional approvals from the Australian Human Research Ethics Committee.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top